STOCK TITAN

InMed Pharmaceuticals Inc - INM STOCK NEWS

Welcome to our dedicated news page for InMed Pharmaceuticals (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on InMed Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect InMed Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of InMed Pharmaceuticals's position in the market.

Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) has been granted an additional 180-day compliance period by Nasdaq to meet the minimum bid price requirement for continued listing. The company must achieve a closing bid price of at least $1.00 per share for 10 consecutive business days by September 16, 2024, to regain compliance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
none
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. reports strong financial results for Q2 fiscal year 2024, with a cash position of US$9.5 million, 164% revenue growth in BayMedica subsidiary, and the advancement of two new preclinical programs for Alzheimer's and AMD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
earnings
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) appoints Ms. Netta Jagpal as Chief Financial Officer and Corporate Secretary, bringing over 20 years of financial leadership experience in the biotech industry. Ms. Jagpal's background includes roles at D-Wave Systems Inc. (NYSE: QBTS) and Zymeworks Inc. (NYSE: ZYME). Her appointment signifies a strategic move to strengthen InMed's financial capabilities and support its core pharmaceutical drug development business and BayMedica's commercial enterprise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
management
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) will participate in the Water Tower Research Fireside Chat Series on January 25, 2024, to discuss its pharmaceutical pipeline in Alzheimer's and ocular, upcoming 2024 milestones, and the role of cannabinoids in Alzheimer's treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. outlines key accomplishments from 2023 and provides strategic priorities for 2024, including the advancement of INM-901 as a treatment for Alzheimer's Disease, the treatment of Age-related Macular Degeneration with INM-089, and seeking partnerships for INM-755 in Dermatology. BayMedica subsidiary continues to focus on revenue growth and market expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.09%
Tags
none
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) confirms approval of all matters at the annual general meeting of shareholders, including the election of all director nominees. A total of 1,292,647 common shares, representing approximately 38.84% of the Company's issued and outstanding common shares, were represented at the Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
none
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) announces the launch of INM-089, a cannabinol (CBN) analog, to investigate its effects in the treatment of Age-related Macular Degeneration (AMD). INM-089 preserved retinal function in an in vivo AMD disease model and improved the thickness of the outer nuclear layer of the retina. The company aims to advance INM-089 to additional in vivo studies as part of the preclinical development program to address the unmet medical need in AMD treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.62%
Tags
none
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. (NASDAQ: INM) reports financial results for Q1 FY2024, highlighting advancements in pharmaceutical programs, commercial operations, and a successful financing round. The company's INM-901 program shows promise in targeting Alzheimer's disease, while the INM-755 CBN cream demonstrates potential for broader applications. BayMedica, the company's commercial subsidiary, experiences robust revenue growth. Financially, the company records a net loss of $2.5M for Q1 FY2024, with a decrease in cash and cash equivalents compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
InMed Pharmaceuticals Inc. announced that their Phase 2 clinical study of investigational drug INM-755 cannabinol cream for the treatment of symptoms in patients with epidermolysis bullosa has been accepted as an oral presentation at the 12th World Congress on Itch. The study showed a positive indication of enhanced anti-itch activity for INM-755 cannabinol cream.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
clinical trial
Rhea-AI Summary
InMed Pharmaceuticals has closed its previously announced offering for the issuance and sale of pre-funded warrants and preferred investment options. The offerings raised approximately $5.2 million in gross proceeds, which will be used for pipeline development, commercial sales, and general working capital purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.93%
Tags
none
InMed Pharmaceuticals Inc

Nasdaq:INM

INM Rankings

INM Stock Data

2.10M
4.84M
1.36%
13.28%
1.09%
Research and Development in Biotechnology (except Nanobiotechnology)
Professional, Scientific, and Technical Services
Link
Canada
Vancouver

About INM

inmed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. inmed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.